Veritas Aortic Solutions

Veritas Aortic Solutions, based in the US, focuses on developing transcatheter therapies that address complex aortic diseases through innovative medical solutions. Founded in 2025 in Costa Mesa, US, Veritas Aortic Solutions specializes in advanced transcatheter therapies for aortic diseases. The company raised USD 12. 000 mn in Seed funding from Cedars-Sinai Health System and others on June 1, 2026, marking its first deal.

The founder's background is not disclosed. Veritas Aortic Solutions specializes in the development of advanced transcatheter therapies aimed at addressing complex aortic diseases. Their core product offering includes the Veritas Transcatheter Valved Aortic Root Conduit (TVARC), designed to provide a minimally invasive solution for conditions that impact the aortic root, coronary arteries, and ascending aorta. This innovative approach seeks to transform treatment options for patients suffering from life-threatening aortic conditions, which are often technically challenging to address through traditional surgical methods.

The company targets healthcare providers within the cardiovascular medicine sector, particularly hospitals and surgical centers that perform cardiac procedures. Geographically, the products are positioned for markets that include North America and Europe, where the need for advanced cardiovascular interventions is significant, and regulatory paths for innovative medical devices are well established. The revenue model of Veritas Aortic Solutions is centered around partnerships and collaborations with healthcare institutions and surgical facilities that utilize their transcatheter therapies. Transactions are structured as direct sales to hospitals, where healthcare providers acquire the Veritas products for use in surgical procedures.

The pricing framework is based on the cost per procedure, which includes the purchase of devices and any additional services associated with the utilization of their technologies. This transactional model emphasizes the flagship TVARC product, which is expected to play a significant role in their revenue generation as it addresses an unmet need in the market. The company’s focus on the development of investigational products suggests a strategy that involves ongoing collaborations with clinical partners to facilitate product adoption and enhance market penetration. In June 2026, Veritas Aortic Solutions raised USD 12.

000 mn in Seed funding, which will be utilized for the development of transcatheter cardiovascular devices for first-in-human clinical use. The company plans to launch new products that are currently in the design phase, with an aim to expand into new markets in North America and Europe by 2027.